Xtant Medical Announces Expiration Of Rights Offering And Estimated Gross Proceeds Of $3.8 Million

BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that the subscription period for its previously announced rights offering (the "Offering") of units at a subscription price of $0.75 per unit expired on November 14, 2016, and these rights are no longer exercisable.

Based on the review of results provided by the Company's subscription agent, Corporate Stock Transfer, Inc., Xtant Medical estimates that it will receive aggregate gross proceeds from the offering of approximately $3.8 million. The results of the Offering and Xtant Medical's estimates regarding the aggregate gross proceeds of the Offering to be received by the Company are preliminary and subject to finalization and verification by its subscription agent.

Xtant Medical anticipates that closing of the Offering will occur on or about Thursday, November 17, 2016, subject to satisfaction or waiver of all conditions to closing. Upon the closing, the subscription agent will distribute, by way of direct registration in book-entry form or through the facilities of the Depositary Trust Company, as applicable, the common stock and warrants to holders of rights who validly exercised their rights and paid the subscription price in full. No physical stock or warrant certificates will be issued to stockholders.

Maxim Group LLC acted as sole dealer manager for the Offering.

If you have questions about the offering, please contact: Maxim Group LLC 405 Lexington Avenue New York, NY 10174 Attention: Syndicate Department Email: syndicate@maximgrp.com Telephone: 212-895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

If you liked this article you might like

Zimmer's LDR Deal Could Force Others to Grow a Dealmaking Spine

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Venture Cap Market Awake, Not Yet Crazy

Venture Cap Market Awake, Not Yet Crazy